nach oben

European Radiology

Erschienen in:

05.05.2017 | Breast

The accuracy of ¹⁸F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review

verfasst von: Fangfang Tian, Guohua Shen, Yunfu Deng, Wei Diao, Zhiyun Jia

Erschienen in: European Radiology | Ausgabe 11/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The aim of this meta-analysis was to evaluate the accuracy of ¹⁸F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients.

Methods

PubMed, Embase, the Cochrane Library (Central), and the Web of Science (SCI-Expanded) were systematically searched to identify pertinent studies. The methodologic quality of the included studies was assessed by the Quality Assessment of Diagnostic Accuracy Studies-2. The Spearman correlation coefficient was used to explore the existence of a threshold effect. Heterogeneity was assessed by the likelihood ratio I ² index.

Results

The pooled values calculated with a mixed-effects model for the sensitivity, specificity and diagnostic odds ratio with 95% confidence intervals were 81.9% (76.0–86.6%), 79.3% (72.1–85.1%) and 17.35 (10.98–27.42), respectively.

Conclusions

¹⁸F-FDG PET/CT has a moderate accuracy in predicting the pathological response during the early process of NAC in breast cancer patients. To increase the role of ¹⁸F-FDG PET/CT in monitoring the therapy response, future prospective studies are needed to explore how chemotherapy regimens and different subtypes affect the levels of glucose metabolism.

Key Points

• This meta-analysis assesses the role of PET/CT in breast cancer during NAC.

• Pathological responses were based on both primary tumour and lymph node.

• ¹⁸ F-FDG PET/CT has a moderate accuracy in predicting the pathological response.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRef

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66:31–42CrossRef

Findlay M, Young H, Cunningham D et al (1996) Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 14:700–708CrossRef

Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608CrossRef

Groheux D, Majdoub M, Sanna A et al (2015) Early metabolic response to neoadjuvant treatment: FDG PET/CT criteria according to breast cancer subtype. Radiology 277:358–371CrossRef

National comprehensive cancer network (2015) Clinical practice guidelines in oncology breast cancer, version 2.2015. Available via http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 20 Oct 2015

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2014) Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm305501.pdf. Accessed 20 Oct 2015

Cameron DA, Anderson ED, Levack P et al (1997) Primary systemic therapy for operable breast cancer—10-year survival data after chemotherapy and hormone therapy. Br J Cancer 76:1099–1105CrossRef

Mieog JS, van der Hage JA, van de Velde CJ (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev 18:Cd005002

10.

Bossuyt V, Provenzano E, Symmans WF et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26:1280–1291CrossRef

11.

Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172CrossRef

12.

Killelea BK, Yang VQ, Mougalian S et al (2015) Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database. J Am Coll Surg 220:1063–1069CrossRef

13.

Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516CrossRef

14.

Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685CrossRef

15.

Schwarz-Dose J, Untch M, Tiling R et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27:535–541CrossRef

16.

Li D, Yao Q, Li L, Wang L, Chen J (2007) Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 6:1442–1448CrossRef

17.

Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11:2101–2111CrossRef

18.

Moreno A, Roman Santamaria JM, Garcia Saez JA et al (2011) Positron emission tomography with computed tomography scanning as a predictor of pathological complete response after neoadjuvant chemotherapy. Eur J Cancer 47:S343CrossRef

19.

Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773–1782CrossRef

20.

Berriolo-Riedinger A, Touzery C, Riedinger JM et al (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34:1915–1924CrossRef

21.

Ueda S, Saeki T, Shigekawa T et al (2012) 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol 17:276–282CrossRef

22.

Wang Y, Zhang C, Liu J, Huang G (2012) Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 131:357–369CrossRef

23.

Cheng X, Li Y, Liu B, Xu Z, Bao L, Wang J (2012) 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Acta Radiol 53:615–627CrossRef

24.

Mghanga FP, Lan X, Bakari KH, Li C, Zhang Y (2013) Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer 13:271–279CrossRef

25.

Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536CrossRef

26.

Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893CrossRef

27.

Rousseau C, Devillers A, Sagan C et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372CrossRef

28.

Choi JH, Lim HI, Lee SK et al (2010) The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 102:392–397CrossRef

29.

Schneider-Kolsky ME, Hart S, Fox J et al (2010) The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 12:R37CrossRef

30.

Buchbender C, Kuemmel S, Hoffmann O et al (2012) FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. Acta Radiol 53:628–636CrossRef

31.

Groheux D, Hindie E, Giacchetti S et al (2012) Triple-negative breast cancer: early assessment with18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53:249–254CrossRef

32.

Humbert O, Berriolo-Riedinger A, Riedinger JM et al (2012) Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 23:2572–2577CrossRef

33.

Tateishi U, Miyake M, Nagaoka T et al (2012) Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging-prospective assessment. Radiology 263:53–63CrossRef

34.

Andrade WP, Lima EN, Osorio CA et al (2013) Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer? Eur J Surg Oncol 39:1358–1363CrossRef

35.

Groheux D, Giacchetti S, Hatt M et al (2013) HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. Br J Cancer 109:1157–1164CrossRef

36.

Groheux D, Hatt M, Hindie E et al (2013) Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer 119:1960–1968CrossRef

37.

Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349CrossRef

38.

Garcia-Esquinas MAG, Garcia JA, Garcia-Saenz JA et al (2014) Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel. Rev Esp Med Nucl Imagen Mol 33:14–21

39.

Groheux D, Hindie E, Giacchetti S et al (2014) Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer 50:1864–1871CrossRef

40.

Humbert O, Cochet A, Riedinger JM et al (2014) HER2-positive breast cancer: (1)(8)F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41:1525–1533CrossRef

41.

Lee SM, Bae SK, Kim TH et al (2014) Value of F-18-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy. Clin Nucl Med 39:882–886CrossRef

42.

Pahk K, Rhee S, Cho J et al (2014) The role of interim 18F-FDG PET/CT in predicting early response to neoadjuvant chemotherapy in breast cancer. Anticancer Res 34:4447–4456PubMed

43.

Connolly RM, Leal JP, Goetz MP et al (2015) TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med 56:31–37CrossRef

44.

Groheux D, Biard L, Giacchetti S et al (2016) 18FDG-PET/CT for the early evaluation of response to neoadjuvant treatment in triple negative breast cancer: influence of the chemotherapy regimen. J Nucl Med 57:536–543CrossRef

45.

Cheng JY, Wang YJ, Mo M et al (2015) 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer. Oncotarget 6:29388–29395PubMedPubMedCentral

46.

Forero-Torres A, Saleh MN, Galleshaw JA et al (2010) Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer. Clin Breast Cancer 10:275–280CrossRef

47.

Champion L, Lerebours F, Alberini JL et al (2015) 18F-FDG PET/CT to predict response to neoadjuvant chemotherapy and prognosis in inflammatory breast cancer. J Nucl Med 56:1315–1321CrossRef

48.

Vicente AMG, Amo-Salas M, Calatayud FR et al (2016) Prognostic role of early and end-of-neoadjuvant treatment F-18-FDG PET/CT in patients with breast cancer. Clin Nucl Med 41:E313–E322CrossRef

49.

Swets JA (1988) Measuring the accuracy of diagnostic systems. Science 240:1285–1293CrossRef

50.

Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960–3966CrossRef

51.

Koolen BB, Pengel KE, Wesseling J et al (2014) Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 41:32–40CrossRef

52.

Avril S, Muzic RF, Plecha D et al (2016) F-18-FDG PET/CT for monitoring of treatment response in breast cancer. J Nucl Med 57:34S–39SCrossRef

53.

Jung SY, Kim SK, Nam BH et al (2010) Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol 17:247–253CrossRef

54.

Provenzano E, Bossuyt V, Viale G et al (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol 28:1185–1201CrossRef

55.

Rouzier R, Extra JM, Klijanienko J et al (2002) Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20:1304–1310CrossRef

56.

Hennessy BT, Hortobagyi GN, Rouzier R et al (2005) Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23:9304–9311CrossRef

57.

Duch J, Fuster D, Munoz M et al (2009) 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 36:1551–1557CrossRef

58.

Sheikhbahaei S, Trahan TJ, Xiao J et al (2016) FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis of diagnostic accuracy studies. Oncologist. doi:10.1634/theoncologist.2015-0353 CrossRefPubMedPubMedCentral

Titel: The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review
verfasst von: Fangfang Tian
Guohua Shen
Yunfu Deng
Wei Diao
Zhiyun Jia
Publikationsdatum: 05.05.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 11/2017
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-017-4831-y

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The accuracy of ¹⁸F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Key Points

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2017

Comparison of 3D magnetic resonance imaging and digital subtraction angiography for intracranial artery stenosis

Do we need 3D tube current modulation information for accurate organ dosimetry in chest CT? Protocols dose comparisons

Interim heterogeneity changes measured using entropy texture features on T2-weighted MRI at 3.0 T are associated with pathological response to neoadjuvant chemotherapy in primary breast cancer

Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification

Preliminary study of diffusion kurtosis imaging in thyroid nodules and its histopathologic correlation

Cardiovascular magnetic resonance myocardial T1 mapping to detect and quantify cardiac involvement in familial amyloid polyneuropathy

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie